

ANTARES PHARMA, INC.  
Form 8-K  
June 11, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2012

**ANTARES PHARMA, INC.**

(Exact name of registrant specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-32302**  
(Commission  
File Number)

**41-1350192**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: ANTARES PHARMA, INC. - Form 8-K

**100 Princeton South, Suite 300, Ewing, NJ**

**(Address of principal executive offices)**

**Registrant's telephone, including area code: (609) 359-3020**

**08628**

**(Zip Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On June 6, 2012 Antares Pharma, Inc. (the Company ) provided written notice to the NYSE Amex Exchange (the NYSE Amex ) that the Company plans to voluntarily transfer its common stock listing to The NASDAQ Stock Market LLC ( NASDAQ ). The Company s common stock, par value \$0.01 per share, has been approved for listing on NASDAQ and is expected to commence trading on NASDAQ on or about June 15, 2012 under the trading symbol ATRS . The Company expects trading to cease on the NYSE Amex effective at the close of business on June 14, 2012.

A copy of the press release issued by the Company on June 6, 2012 is attached hereto as Exhibit 99.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

(99) Press Release, dated June 6, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTARES PHARMA, INC.**

Date: June 11, 2012

By: /s/ Paul K. Wotton  
Name: Dr. Paul K. Wotton

Title: President and Chief Executive Officer